$-0.32 EPS Expected for Aldeyra Therapeutics, Inc. (ALDX)

March 14, 2018 - By Stephen Andrade

 $ 0.32 EPS Expected for Aldeyra Therapeutics, Inc. (ALDX)
Investors sentiment increased to 3.13 in Q3 2017. Its up 1.46, from 1.67 in 2017Q2. It improved, as 3 investors sold Aldeyra Therapeutics, Inc. shares while 5 reduced holdings. 11 funds opened positions while 14 raised stakes. 18.26 million shares or 145.50% more from 7.44 million shares in 2017Q2 were reported.
Manufacturers Life Communications The accumulated 0% or 1,612 shares. Weiss Multi owns 50,000 shares. Hikari Limited accumulated 107,858 shares. Morgan Stanley has invested 0% in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX). New York-based Millennium Mngmt Lc has invested 0.01% in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX). 50,728 are held by Two Sigma Securities Ltd. Tower Research Capital Ltd Com (Trc) reported 3,183 shares or 0% of all its holdings. Woodstock Corp has 48,393 shares. Drw Ltd Liability Corp reported 12,000 shares or 0.03% of all its holdings. 725 were reported by Alphaone Investment Services Llc. Sphera Funds reported 1.07% in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX). Blackrock Inc has invested 0% in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX). Adage Capital Ptnrs Grp Limited Com has invested 0.01% of its portfolio in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX). Jane Street Group Lc reported 10,961 shares. 683 Mngmt Ltd Liability holds 0.63% in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) or 835,514 shares.

Since September 19, 2017, it had 1 buy, and 0 selling transactions for $1.45 million activity.

Analysts expect Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) to report $-0.32 EPS on March, 29.They anticipate $0.04 EPS change or 11.11 % from last quarter’s $-0.36 EPS. After having $-0.32 EPS previously, Aldeyra Therapeutics, Inc.’s analysts see 0.00 % EPS growth. It closed at $8.85 lastly. It is down 18.94% since March 15, 2017 and is downtrending. It has underperformed by 35.64% the S&P500.

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) Ratings Coverage

Among 6 analysts covering Aldeyra Therapeutics Inc (NASDAQ:ALDX), 6 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Aldeyra Therapeutics Inc had 13 analyst reports since August 13, 2015 according to SRatingsIntel. The firm earned “Buy” rating on Monday, September 26 by H.C. Wainwright. The stock has “Buy” rating by Cowen & Co on Thursday, September 14. H.C. Wainwright maintained the shares of ALDX in report on Wednesday, August 9 with “Buy” rating. H.C. Wainwright maintained the stock with “Buy” rating in Thursday, June 15 report. Stifel Nicolaus initiated Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) on Friday, July 1 with “Buy” rating. The company was maintained on Wednesday, August 9 by Cowen & Co. Cowen & Co initiated Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) rating on Tuesday, September 8. Cowen & Co has “Outperform” rating and $15 target. The rating was maintained by Cantor Fitzgerald on Thursday, November 9 with “Buy”. Canaccord Genuity maintained the shares of ALDX in report on Wednesday, June 14 with “Buy” rating. Cantor Fitzgerald initiated the shares of ALDX in report on Tuesday, October 24 with “Buy” rating.

Aldeyra Therapeutics, Inc., a biotechnology company, focuses on the development of products for inflammation, inborn errors of metabolism, and other diseases in the United States and internationally. The company has market cap of $169.19 million. It is developing ADX-102, a small molecule designed to trap and allow for the degradation of aldehydes, as well as ADX-103 and ADX-104 novel candidates for the treatment of noninfectious anterior uveitis, allergic conjunctivitis, dry eye syndrome, sjögren-larsson syndrome, and succinic semi-aldehyde dehydrogenase deficiency. It currently has negative earnings. The firm was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014.

More notable recent Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) news were published by: Seekingalpha.com which released: “A Second Chance To Get In On Aldeyra Therapeutics” on September 19, 2017, also Prnewswire.com with their article: “Aldeyra Therapeutics Selected for Podium Presentation of Phase 2a Dry Eye …” published on February 21, 2018, Marketwatch.com published: “Aldeyra Therapeutics’ stock soars after positive results of dry eye disease …” on September 12, 2017. More interesting news about Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) were released by: Seekingalpha.com and their article: “Aldeyra Therapeutics: Multiple Clinical Catalysts Make This A Buy” published on January 27, 2018 as well as Streetinsider.com‘s news article titled: “Aldeyra Therapeutics (ALDX) Announces Pact with Janssen for Systemic …” with publication date: February 27, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: